Adial Pharmaceuticals Inc (ADIL) Expected to Post Earnings of -$0.40 Per Share

Share on StockTwits

Equities research analysts expect Adial Pharmaceuticals Inc (NASDAQ:ADIL) to post ($0.40) earnings per share for the current quarter, according to Zacks. Zero analysts have made estimates for Adial Pharmaceuticals’ earnings. The business is scheduled to report its next earnings report on Wednesday, March 20th.

On average, analysts expect that Adial Pharmaceuticals will report full-year earnings of ($1.32) per share for the current fiscal year. For the next year, analysts expect that the company will post earnings of ($0.31) per share. Zacks’ earnings per share averages are an average based on a survey of sell-side research firms that cover Adial Pharmaceuticals.

Several equities research analysts recently issued reports on ADIL shares. Maxim Group restated a “buy” rating and issued a $5.00 target price on shares of Adial Pharmaceuticals in a report on Thursday, December 13th. ValuEngine cut shares of Adial Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, December 21st.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Geode Capital Management LLC bought a new position in Adial Pharmaceuticals in the fourth quarter worth approximately $69,000. Two Sigma Investments LP bought a new position in Adial Pharmaceuticals in the fourth quarter worth approximately $60,000. Finally, BlackRock Inc. bought a new position in Adial Pharmaceuticals in the fourth quarter worth approximately $1,053,000. Institutional investors and hedge funds own 3.80% of the company’s stock.

ADIL stock traded down $0.15 on Friday, hitting $3.48. The company had a trading volume of 13,702 shares, compared to its average volume of 631,444. Adial Pharmaceuticals has a 12-month low of $1.11 and a 12-month high of $9.44.

Adial Pharmaceuticals Company Profile

Adial Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic agents for the treatment of alcohol use disorders. Its lead product is AD04, a selective serotonin-3 antagonist that has completed Phase IIb clinical trials for the treatment of nausea and emesis.

Recommended Story: How does the Federal Reserve determine interest rates?

Get a free copy of the Zacks research report on Adial Pharmaceuticals (ADIL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Adial Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adial Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Aptinyx  Lowered to Hold at Zacks Investment Research
Aptinyx Lowered to Hold at Zacks Investment Research
Cetera Investment Advisers Acquires 1,123 Shares of NextEra Energy Inc
Cetera Investment Advisers Acquires 1,123 Shares of NextEra Energy Inc
KBR  Downgraded by Zacks Investment Research to “Hold”
KBR Downgraded by Zacks Investment Research to “Hold”
ARK Web x.0 ETF  Shares Sold by Cetera Advisor Networks LLC
ARK Web x.0 ETF Shares Sold by Cetera Advisor Networks LLC
Cetera Advisors LLC Invests $315,000 in iShares Global Consumer Staples ETF
Cetera Advisors LLC Invests $315,000 in iShares Global Consumer Staples ETF
Cetera Advisor Networks LLC Boosts Stake in Canadian National Railway
Cetera Advisor Networks LLC Boosts Stake in Canadian National Railway


© 2006-2019 Ticker Report